IPH6401 / SAR'514
Not specified (ANKET® program)
Phase 1/2Active, sponsored by Sanofi
Key Facts
Indication
Not specified (ANKET® program)
Phase
Phase 1/2
Status
Active, sponsored by Sanofi
Company
About Innate Pharma
Founded in 1999 by pioneering immunologists, Innate Pharma is a Nasdaq and Euronext-listed biotech focused on harnessing the innate immune system to fight cancer. The company has built a robust pipeline of proprietary and partnered assets, including lacutamab (anti-KIR3DL2), IPH4502 (Nectin-4 ADC), and monalizumab (anti-NKG2A, partnered with AstraZeneca). Its strategy is underpinned by strong scientific foundations, strategic collaborations with major players like AstraZeneca and Sanofi, and a leadership team with deep industry and scientific expertise.
View full company profileTherapeutic Areas
Other Not specified (ANKET® program) Drugs
| Drug | Company | Phase |
|---|---|---|
| IPH6101 / SAR'579 | Innate Pharma | Phase 1/2 |